Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504439-42-00

Acronym

PLACONCANALDE

Enrollment

118

Registered

2024-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alcohol dependence

Brief summary

To evaluate CBD efficacy on alcohol dependance, To evaluate psychological symptoms involved in alcohol consumptions, To evaluate endocannabinoid system, To evaluate CBD tolerability and safety in alcohol dependents

Interventions

DRUGPlacebo to cannabidiol

DRUGCannabidiol

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To evaluate CBD efficacy on alcohol dependance, To evaluate psychological symptoms involved in alcohol consumptions, To evaluate endocannabinoid system, To evaluate CBD tolerability and safety in alcohol dependents	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026